IL-2 immunotherapy in chronically SIV-infected Rhesus Macaques

Virology Journal

Jérôme Estaquier¹  Yves Lévy²  Laure Campillo-Gimenez⁴  Shahul Mouhamad⁴  Ricardo Silvestre⁵  Mireille Laforge³  Julie Garibal⁴ 

[1] Université Laval, Centre de recherche en Infectiologie, Québec, Canada;Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Henri-Mondor Albert-Chenevier, service d’immunologie clinique, Créteil, F-94010, France;CNRS FRE 3235, Université Paris Descartes, Paris, France;INSERM U955 Equipe 16, Institut Mondor de Recherche Biomédicale, Créteil, F-94010, France;Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal

关键词: Treg;    Fas;    Apoptosis;    T cells;    IL-2 immunotherapy;    SIV;   

Others  :  1153667
DOI  :  10.1186/1743-422X-9-220

 received in 2012-02-03, accepted in 2012-09-14,  发布年份 2012

【 摘 要 】

Background

Despite inducing a sustained increase in CD4+ T cell counts, intermittent recombinant IL-2 (rIL-2) therapy did not confer a better clinical outcome in HIV-infected patients enrolled in large phase III clinical trials ESPRIT and SILCAAT. Several hypotheses were evoked to explain these discrepancies. Here, we investigated the impact of low and high doses of IL-2 in Rhesus macaques of Chinese origin infected with SIVmac251 in the absence of antiretroviral therapy (ART).

Results

We demonstrated that rIL-2 induced a dose dependent expansion of CD4+ and CD8+ T cells without affecting viral load. rIL-2 increased CD4 and CD8 Treg cells as defined by the expression of CD25^highFoxP3⁺CD127^low. We also showed that rIL-2 modulated spontaneous and Fas-mediated CD4⁺ and CD8⁺ T cell apoptosis. The higher dose exhibited a dramatic pro-apoptotic effect on both CD4⁺ and CD8⁺ T cell populations. Finally, all the animals treated with rIL-2 developed a wasting syndrome in the month following treatment simultaneously to a dramatic decrease of circulating effector T cells.

Conclusion

These data contribute to the understanding of the homeostatic and dosage effects of IL-2 in the context of SIV/HIV infection.

【 授权许可】

   
2012 Garibal et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Hurtrel B, Petit F, Arnoult D, Muller-Trutwin M, Silvestri G, Estaquier J: Apoptosis in SIV infection. Cell Death Differ 2005, 12(Suppl 1):979-990.
• [2]Giralt M, Diaz-Delfin J, Gallego-Escuredo JM, Villarroya J, Domingo P, Villarroya F: Lipotoxicity on the basis of metabolic syndrome and lipodystrophy in HIV-1-infected patients under antiretroviral treatment. Curr Pharm Des 2010, 16:3371-3378.
• [3]Veloso S, Peraire J, Vilades C, Lopez-Dupla M, Escote X, Olona M, Garcia-Pardo G, Gomez-Bertomeu F, Soriano A, Sirvent JJ, Vidal F: Pharmacogenetics of the metabolic disturbances and atherosclerosis associated with antiretroviral therapy in HIV-infected patients. Curr Pharm Des 2010, 16:3379-3389.
• [4]Muro-Cacho CA, Pantaleo G, Fauci AS: Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J Immunol 1995, 154:5555-5566.
• [5]Ledru E, Lecoeur H, Garcia S, Debord T, Gougeon ML: Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: correlation with Bcl-2 expression and consequences for AIDS pathogenesis. J Immunol 1998, 160:3194-3206.
• [6]Estaquier J, Idziorek T, Zou W, Emilie D, Farber CM, Bourez JM, Ameisen JC: T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. J Exp Med 1995, 182:1759-1767.
• [7]Estaquier J, Tanaka M, Suda T, Nagata S, Golstein P, Ameisen JC: Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. Blood 1996, 87:4959-4966.
• [8]Arnoult D, Petit F, Lelievre JD, Lecossier D, Hance A, Monceaux V, Hurtrel B, Ho Tsong Fang R, Ameisen JC, Estaquier J: Caspase-dependent and -independent T-cell death pathways in pathogenic simian immunodeficiency virus infection: relationship to disease progression. Cell Death Differ 2003, 10:1240-1252.
• [9]Boudet F, Lecoeur H, Gougeon ML: Apoptosis associated with ex vivo down-regulation of Bcl-2 and up-regulation of Fas in potential cytotoxic CD8+ T lymphocytes during HIV infection. J Immunol 1996, 156:2282-2293.
• [10]Zaunders JJ, Moutouh-de Parseval L, Kitada S, Reed JC, Rought S, Genini D, Leoni L, Kelleher A, Cooper DA, Smith DE, et al.: Polyclonal proliferation and apoptosis of CCR5+ T lymphocytes during primary human immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2. J Infect Dis 2003, 187:1735-1747.
• [11]Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC, Gougeon ML: Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000, 95:3191-3198.
• [12]Lenardo MJ: Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 1991, 353:858-861.
• [13]Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I: Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991, 352:621-624.
• [14]Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA, Fauci AS: The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008, 181:6738-6746.
• [15]Petit F, Arnoult D, Lelievre JD, Moutouh-de Parseval L, Hance AJ, Schneider P, Corbeil J, Ameisen JC, Estaquier J: Productive HIV-1 infection of primary CD4+ T cells induces mitochondrial membrane permeabilization leading to a caspase-independent cell death. J Biol Chem 2002, 277:1477-1487.
• [16]Zou W, Foussat A, Houhou S, Durand-Gasselin I, Dulioust A, Bouchet L, Galanaud P, Levy Y, Emilie D: Acute upregulation of CCR-5 expression by CD4+ T lymphocytes in HIV-infected patients treated with interleukin-2. ANRS 048 IL-2 study group. AIDS 1999, 13:455-463.
• [17]Levy Y, Durier C, Lascaux AS, Meiffredy V, Gahery-Segard H, Goujard C, Rouzioux C, Resch M, Guillet JG, Kazatchkine M, et al.: Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006, 20:405-413.
• [18]Gougeon ML, Rouzioux C, Liberman I, Burgard M, Taoufik Y, Viard JP, Bouchenafa K, Capitant C, Delfraissy JF, Levy Y: Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patients. AIDS 2001, 15:1729-1731.
• [19]Farel CE, Chaitt DG, Hahn BK, Tavel JA, Kovacs JA, Polis MA, Masur H, Follmann DA, Lane HC, Davey RT Jr: Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood 2004, 103:3282-3286.
• [20]Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, Michon C, Oksenhendler E, Weiss L, Gastaut JA, et al.: Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 2003, 17:343-351.
• [21]Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Sereti I, Sachau W, Kelly G, Metcalf JA, Davey RT Jr, Falloon J, et al.: Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 2005, 115:2139-2148.
• [22]Sereti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani MS, Badralmaa Y, Berg SC, Metcalf JA, Hahn BK, Shen JM, et al.: In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 2005, 115:1839-1847.
• [23]Weiss L, Letimier FA, Carriere M, Maiella S, Donkova-Petrini V, Targat B, Benecke A, Rogge L, Levy Y: In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients. Proc Natl Acad Sci USA 2010, 107:10632-10637.
• [24]Abrams D, Levy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, et al.: Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009, 361:1548-1559.
• [25]Marshak-Rothstein A, Stanger BZ, Sherr DH, Ju ST, Panka DJ, Cui H, Ettinger R, Khatib M: as(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995, 373:444-448.
• [26]Lelievre JD, Mammano F, Arnoult D, Petit F, Grodet A, Estaquier J, Ameisen JC: A novel mechanism for HIV1-mediated bystander CD4+ T-cell death: neighboring dying cells drive the capacity of HIV1 to kill noncycling primary CD4+ T cells. Cell Death Differ 2004, 11:1017-1027.
• [27]Viollet L, Monceaux V, Petit F, Ho Tsong Fang R, Cumont MC, Hurtrel B, Estaquier J: Death of CD4+ T cells from lymph nodes during primary SIVmac251 infection predicts the rate of AIDS progression. J Immunol 2006, 177:6685-6694.
• [28]Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT Jr, Falloon J, Polis MA, Walker RE, Stevens R, Salzman NP, et al.: ncreases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995, 332:567-575.
• [29]Go R, Steigbigel R: Interleukin 2 and HIV RNA Levels. Arch Intern Med 2007, 167:2144-2145. author reply 2145
• [30]Molina JM, Levy Y, Fournier I, Hamonic S, Bentata M, Beck-Wirth G, Gougeon ML, Venet A, Madelaine I, Sereni D, et al.: Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119). J Infect Dis 2009, 200:206-215.
• [31]Youle M, Emery S, Fisher M, Nelson M, Fosdick L, Janossy G, Loveday C, Sullivan A, Herzmann C, Wand H, et al.: A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard study. PLoS Clin Trials 2006, 1:e3.
• [32]Leger-Ravet MB, Mathiot C, Portier A, Brandely M, Galanaud P, Fridman WH, Emilie D: Increased expression of perforin and granzyme B genes in patients with metastatic melanoma treated with recombinant interleukin-2. Cancer Immunol Immunother 1994, 39:53-58.
• [33]Romano F, Piacentini MG, Franciosi C, Caprotti R, De Fina S, Cesana G, Uggeri F, Conti M, Uggeri F: Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients. Hepatogastroenterology 2004, 51:1872-1876.
• [34]Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, Robinson BW, Nelson DJ: IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol 2003, 171:5051-5063.
• [35]Carcelain G, Saint-Mezard P, Altes HK, Tubiana R, Grenot P, Rabian C, de Boer R, Costagliola D, Katlama C, Debre P, Autran B: IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients with severe CD4 lymphopenia. AIDS 2003, 17:841-850.
• [36]Herzmann C, Cuthbertson Z, Fosdick L, Fisher M, Nelson M, Perry N, Law M, Wand H, Janossy G, Johnson MA, Youle M: Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2008, 62:583-586.
• [37]Chase AJ, Yang HC, Zhang H, Blankson JN, Siliciano RF: Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol 2008, 82:8307-8315.
• [38]Moreno-Fernandez ME, Rueda CM, Rusie LK, Chougnet CA: Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism. Blood 2011, 117:5372-5380.
• [39]Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF: Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 2004, 78:2454-2459.
• [40]Kinter A, McNally J, Riggin L, Jackson R, Roby G, Fauci AS: Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals. Proc Natl Acad Sci USA 2007, 104:3390-3395.
• [41]Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y: Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 2004, 104:3249-3256.
• [42]Elahi S, Dinges WL, Lejarcegui N, Laing KJ, Collier AC, Koelle DM, McElrath MJ, Horton H: Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat Med 2011, 17:989-995.
• [43]Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC, Pollard RB, Somsouk M, Deeks SG, Shacklett BL: Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers. J Virol 2011, 85:11422-11434.
• [44]Favre D, Lederer S, Kanwar B, Ma ZM, Proll S, Kasakow Z, Mold J, Swainson L, Barbour JD, Baskin CR, et al.: Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog 2009, 5:e1000295.
• [45]Estes JD, Li Q, Reynolds MR, Wietgrefe S, Duan L, Schacker T, Picker LJ, Watkins DI, Lifson JD, Reilly C, et al.: Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J Infect Dis 2006, 193:703-712.
• [46]Cumont MC, Monceaux V, Viollet L, Lay S, Parker R, Hurtrel B, Estaquier J: TGF-beta in intestinal lymphoid organs contributes to the death of armed effector CD8 T cells and is associated with the absence of virus containment in rhesus macaques infected with the simian immunodeficiency virus. Cell Death Differ 2007, 14:1747-1758.
• [47]Campillo-Gimenez L, Cumont MC, Fay M, Kared H, Monceaux V, Diop O, Müller-Trutwin M, Hurtrel B, Lévy Y, Zaunders J, Dy M, Leite-de-Moraes MC, Elbim C, Estaquier J: AIDS progression is associated with the emergence of IL-17-producing cells early after simian immunodeficiency virus infection. J Immunol 2010, 184:984-92.
• [48]Nigam P, Velu V, Kannanganat S, Chennareddi L, Kwa S, Siddiqui M, Amara RR: Expansion of FOXP3+ CD8 T cells with suppressive potential in colorectal mucosa following a pathogenic simian immunodeficiency virus infection correlates with diminished antiviral T cell response and viral control. J Immunol 2010, 184:1690-1701.
• [49]Foureau DM, McKillop IH, Jones CP, Amin A, White RL, Salo JC: Skin tumor responsiveness to interleukin-2 treatment and CD8 Foxp3+ T cell expansion in an immunocompetent mouse model. Cancer Immunol Immunother 2011, 60:1347-1356.
• [50]Sereti I, Herpin B, Metcalf JA, Stevens R, Baseler MW, Hallahan CW, Kovacs JA, Davey RT, Lane HC: CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients. AIDS 2001, 15:1765-1775.
• [51]Pandolfi F, Pierdominici M, Marziali M, Livia Bernardi M, Antonelli G, Galati V, D'Offizi G, Aiuti F: Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART. Clin Immunol 2000, 94:153-159.
• [52]Poonia B, Salvato MS, Yagita H, Maeda T, Okumura K, Pauza CD: Treatment with anti-FasL antibody preserves memory lymphocytes and virus-specific cellular immunity in macaques challenged with simian immunodeficiency virus. Blood 2009, 114:1196-1204.
• [53]Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel MR, Delwart E, Sepulveda H, Balderas RS, et al.: Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006, 12:1198-1202.
• [54]Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, et al.: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
• [55]Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC, Precopio ML, Schacker T, Roederer M, Douek DC, Koup RA: PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006, 203:2281-2292.
• [56]Laforge M, Campillo-Gimenez L, Monceaux V, Cumont MC, Hurtrel B, Corbeil J, Zaunders J, Elbim C, Estaquier J: HIV/SIV infection primes monocytes and dendritic cells for apoptosis. PLoS Pathog 2011, 7:e1002087.
• [57]Monceaux V, Viollet L, Petit F, Ho Tsong Fang R, Cumont MC, Zaunders J, Hurtrel B, Estaquier J: CD8+ T cell dynamics during primary simian immunodeficiency virus infection in macaques: relationship of effector cell differentiation with the extent of viral replication. J Immunol 2005, 174:6898-6908.